ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting

    Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort

    Jeffrey A. Sparks1, Shun-Chiao Chang2, Kevin D. Deane3, Ryan W. Gan4, Kristen Demoruelle3, Marie L. Feser3, LauraKay Moss3, Jane H. Buckner5, Richard M. Keating6, Karen H. Costenbader7, Peter K. Gregersen8, Michael H. Weisman9, Ted R. Mikuls10, James R. O'Dell10, V. Michael Holers3, Jill M. Norris4 and Elizabeth W. Karlson2, 1Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Epidemiology, Colorado School of Public Health, Aurora, CO, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Division of Rheumatology, Scripps Health, La Jolla, CA, 7Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 8Feinstein Insititute for Medical Research, Manhasset, NY, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
  • Abstract Number: 1211 • 2015 ACR/ARHP Annual Meeting

    Shift of Rheumatoid Arthritis Onset Toward Old Age in Japan Based on a Nationwide Cohort Database

    Eri Kimura1, Tetsuji Sawada2, Koichiro Tahara1, Haeru Hayashi1, Mayu Tago1, Hiroaki Mori1, Toshihiro Matsui3, Jinju Nishino4 and Shigeto Tohma5, 1Rheumatology, Tokyo Medical University, Tokyo, Japan, 2Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, 3Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Kanagawa, Japan, 4Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan

    Background/Purpose: Previous studies from Western countries have demonstrated that the incidence of rheumatoid arthritis (RA) increases with age and the age of RA onset was…
  • Abstract Number: 1212 • 2015 ACR/ARHP Annual Meeting

    Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis

    Elizabeth A. Bemis1, Ryan W. Gan2, Marie L. Feser3, Michael H. Weisman4, James R. O'Dell5, Ted R. Mikuls5, Jane H. Buckner6, Peter K. Gregersen7, Richard M. Keating8, M. Kristen Demoruelle9, Kevin D. Deane10, V. Michael Holers11 and Jill M. Norris12, 1Epidemiology, Epidemiology, Colorado School of Public Health, Aurora, CO, 2Colorado School of Public Health, University of Colorado Denver, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5University of Nebraska Medical Center, Omaha, NE, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Feinstein Insititute for Medical Research, Manhasset, NY, 8Division of Rheumatology, Scripps Health, La Jolla, CA, 9Rheumatology, University of Colorado School of Medicine, Aurora, CO, 10Division of Rheumatology, U Colo Denver, Aurora, CO, 11Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, 12University of Colorado Denver, Aurora, CO

    Background/Purpose: Vitamin D has immunomodulatory properties, and could be a protective factor against rheumatoid arthritis (RA). Anti-cyclic citrullinated peptide (anti-CCP) autoantibodies and swollen small joints…
  • Abstract Number: 1213 • 2015 ACR/ARHP Annual Meeting

    Prospective Study of Dietary Patterns and Risk of Rheumatoid Arthritis in Women

    Bing Lu1, Yang Hu2, Jeffrey A. Sparks3, Karen H. Costenbader4, Frank Hu5 and Elizabeth W. Karlson1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Nutrition, Harvard School of Public Health, Boston, MA, 3Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Harvard School of Public Health, Boston, MA

    Background/Purpose: Although some individual dietary factors have been identified to be associated with the development of rheumatoid arthritis (RA), few studies have examined the effects…
  • Abstract Number: 1214 • 2015 ACR/ARHP Annual Meeting

    Rheumatoid Arthritis in Female Spouses in the Agricultural Health Study: Associations with Pesticides and Other Farm Exposures

    Christine G. Parks1, Jane Hoppin2, Karen H. Costenbader3 and Dale Sandler4, 1Epidemiology Branch, National Institute of Environmental Health Science, Research Triangle Park, NC, 2Biological Sciences, North Carolina State University, Raleigh, NC, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Epidemiology Branch, NIH/NIEHS, Research Triangle Park, NC

    Background/Purpose: Farming has been associated with rheumatoid arthritis (RA), but the role of pesticides is not known. We examined associations between RA, pesticides and other…
  • Abstract Number: 1215 • 2015 ACR/ARHP Annual Meeting

    Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis

    Gavin Sun1, Glen Hazlewood2, Sasha Bernatsky3, Gilaad Kaplan4, Bertus Eksteen5 and Cheryl Barnabe2, 1Department of Internal Medicine, University of Calgary, Calgary, AB, Canada, 2Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 3Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, 4Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, 5Division of Hepatology, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Environmental risk factors, such as air pollution, have been studied in relation to the risk of development of rheumatic diseases, including rheumatoid arthritis (RA),…
  • Abstract Number: 1216 • 2015 ACR/ARHP Annual Meeting

    The Clinical and Ultrasonographic Presentation of Seronegative RA Is More Severe Compared to Seropositive RA in an Inception Cohort of DMARD-Naïve Patients Classified According to the 2010 ACR/EULAR Criteria

    Lena B. Nordberg1, Siri Lillegraven1, Elisabeth Lie1, Anna-Birgitte Aga2, Inge C Olsen2, Hilde Berner Hammer3, Till Uhlig1, Désirée van der Heijde4, Tore K. Kvien1, Espen A. Haavardsholm1 and the ARCTIC Study Group, 1Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 2Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 4Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The development of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA) has led to a redefinition of the patient population, including classification of…
  • Abstract Number: 1217 • 2015 ACR/ARHP Annual Meeting

    Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis

    Katherine Liao1, Jeffrey A. Sparks1, Boris Hejblum2, I-Hsin Kuo1, Jing Cui1, Lauren J. Lahey3, Andrew Cagan4, Vivian Gainer4, Weidong Liu5, Tony Cai6, Jeremy Sokolove7 and Tianxi Cai2, 1Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA, 2Biostatistics, Harvard School of Public Health, Boston, MA, 3Medicine, VA Palo Alto HealthCare System and Stanford University, Palo Alto, CA, 4Research Computing, Partners HealthCare, Charlestown, MA, 5Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China, 6Statistics, University of Pennsylvania, Philadelphia, PA, 7Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA

    Background/Purpose: RA patients develop autoantibodies against a spectrum of antigens.  However, the clinical significance of these autoantibodies after RA diagnosis is unclear.  The Phenome-Wide Association…
  • Abstract Number: 1218 • 2015 ACR/ARHP Annual Meeting

    Higher Education Is Associated with a Better Rheumatoid Arthritis Outcome Concerning Pain and Function but Not Disease Activity: Results from Swedish Registers

    Xia Jiang1, Maria Sandberg2, Saedis Saevarsdottir3, Lars Alfredsson4, Lars Klareskog5 and Camilla Bengtsson6, 1Karolinska Institutet, Stockholm, Sweden, 2Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Unit of Cardiovascular Epidemiology, Institute of Enviornmental Medicine, Karolinska Institutet, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 6The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: To investigate the influence of education (achieving university/college degree (high) or not (low)) on the outcomes of early RA, in terms of disease activity,…
  • Abstract Number: 1219 • 2015 ACR/ARHP Annual Meeting

    Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Poland: First Nationwide Study

    Bogdan Batko1, Marcin Stajszczyk2, Jerzy Swierkot3, Filip Raciborski4 and Piotr Wiland3, 1Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland, 2Department of Reumatology and Autoimmune Diseases, Silesian Rheumatology Center, Ustron, Poland, 3Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, 4Department of Epidemiology and Health Promotion, Institute of Rheumatology, Warsaw, Poland

    Background/Purpose: The prevalence of rheumatoid arthritis (RA) in Europe varies from a geographical standpoint. Knowledge of the occurrence of RA is valuable for policy makers…
  • Abstract Number: 1220 • 2015 ACR/ARHP Annual Meeting

    Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis

    Rachel J Black1,2, Rebecca M Joseph3,4, Mohammad Movahedi2, Mark Lunt2 and William G Dixon2,5, 1Department of Medicine, The University of Adelaide, Adelaide, Australia, 2Manchester Academic Health Sciences Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 3Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 4NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 5Manchester Academic Health Sciences Centre, Health e-Research Centre, Farr Institute for Health Informatics Research, The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA). Although GPs don’t typically alter DMARD prescriptions, changes to GC therapy…
  • Abstract Number: 1221 • 2015 ACR/ARHP Annual Meeting

    Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea

    Yoon-Kyoung Sung1, Soo-Kyung Cho1, Soyoung Won2, Chan-Bum Choi3, So-Young Bang4, Seung-Jae Hong5, Hyoun-Ah Kim6, Eunmi Koh7, Hye-Soon Lee8, Chang-Hee Suh9, Dae-Hyun Yoo10, Sang-Cheol Bae1 and BIOPSY investigators, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Hanyang University Guri Hospital, Guri, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea, 6Ajou University Hospital, Suwon, South Korea, 7Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 8Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, 9Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, 10Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

    Background/Purpose: Recently biosimilar infliximab was approved in South Korea and it has been commonly used for rheumatoid arthritis (RA) patients who are resistant to conventional…
  • Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting

    The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment

    Soo-Kyung Cho1, Dam Kim1, Hye-Jin Jeong2, Il Woong Sohn2, Soyoung Won3, Minkyung Han3, Jiyoung Lee3, Eun Jin Jang4, Sang-Cheol Bae1 and Yoon-Kyoung Sung1, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Information Statistics, Andong National University, Andong-si, South Korea

    Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
  • Abstract Number: 1224 • 2015 ACR/ARHP Annual Meeting

    Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases

    Sintawat Wangsiricharoen1, Colin Ligon2, Ahmad Dehrab3, Lydia Gedmintas4, Marisa Tungsiripat5, Clifton Bingham6, Carlos J. Lozada7 and Leonard H. Calabrese8, 1Chiang Mai University, Chiang Mai, Thailand, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Rheumatology, University of Miami Jackson Memorial Hospital, Miami, FL, 4Rheumatology, Brigham's Women's Hospital, Boston, MA, 5Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, 6Johns Hopkins University, Baltimore, MD, 7University of Miami Miller School of Medicine, Miami, FL, 8Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Few HIV-infected patients have been treated with tumor necrosis factor (TNF)-α inhibitor therapy for autoimmune diseases refractory to conventional therapies. Evidence supporting the safety…
  • Abstract Number: 1225 • 2015 ACR/ARHP Annual Meeting

    Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data

    Laurent Chanroux, Joan Casellas and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom

    Background/Purpose: Biologics (bDMARDs) have been shown to control disease progression in RA however there is still no cure for the disease and in many cases…
  • « Previous Page
  • 1
  • …
  • 1768
  • 1769
  • 1770
  • 1771
  • 1772
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology